2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3066

Clinical Features and Treatments of Takayasu Arteritis Complicated with Ulcerative Colitis
Abstract Number: 3067

Microscopic Colitis in Patients with Takayasu Arteritis; A Potential Association Between the Two Disease Entities
Abstract Number: 3068

Damage Assessment in Takayasu’s Arteritis
Abstract Number: 3069

Long Term Follow-up Results of Endovascular Repair in the Management of Arterial Stenosis Caused By Takayasu Arteritis
Abstract Number: 3070

Outcome of Pregnancies in Patients with Takayasu Arteritis with Special Focus on Risk Factors and Disease Activity
Abstract Number: 3071

Takayasu’s Arteritis and Pregnancy
Abstract Number: 3072

Childhood Takayasu Arteritis. a Single Center Experience
Abstract Number: 3073

Patterns of Vascular Involvement in Childhood Takayasu Arteritis
Abstract Number: 3074

The Shared Rheumatoid Arthritis HLA-DRB1 Susceptibility Epitope Shapes the Molecular Orientation of Citrulline and the Autoreactive T Cell Receptor Repertoire
Abstract Number: 3075

Salivary Gland FcRL4+ B-Cells Are a Potential Source of Progenitor Cells for MALT Lymphoma in Primary Sjögren’s Syndrome
Abstract Number: 3076

Interferon Gamma (IFNg) Is the Driving Mediator of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in TLR9-Mediated Pathogenesis in Mice and Is Correlated to Disease Parameters in Children
Abstract Number: 3077

Anakinra in Patients with Cortico-Dependent Idiopathic Recurrent Pericarditis: A Randomised Double-Blind Placebo-Controlled Withdrawal Trial
Abstract Number: 3078

ABCG2 rs2231142 predicts Poor Response to Allopurinol in Patients with Gout
Abstract Number: 3079

Efficacy and Safety of Riociguat in Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disease (CTD)
Abstract Number: 3080

Histone H2AX Phosphorylation As a Measure of DNA Double Strand Breaks and a Marker of Environmental Stress and Disease Activity in Lupus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].